Blinatumomab meets endpoint early in ALL
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The success of Micromet's blinatumomab meeting the primary endpoint in a Phase II study in acute lymphocytic leukemia is being viewed by investors as "striking" results. The study tested the BiTE antibody in 21 patients with minimal residual disease - that is, patients who retain a detectable level of ALL cells in the bone marrow after chemotherapy. Results reported in Berlin at the European Hematology Association June 8 showed that 13 of 16 patients evaluated so far, 81 percent, yielded a response. The study had only to show at least 22 percent response to achieve the primary efficacy endpoint. Patients in all subgroups responded to treatment with blinatumomab. Micromet also is testing the biologic in non-Hodgkin's lymphoma
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.